Hygroton - Medsafe
... treatment, serum potassium concentrations should be monitored at the start of therapy and then after 3-4 weeks. Thereafter, if the potassium balance is not disturbed by additional factors (e.g. vomiting, diarrhoea, change in renal function, etc.) checks should be carried out every 4-6 months. If nec ...
... treatment, serum potassium concentrations should be monitored at the start of therapy and then after 3-4 weeks. Thereafter, if the potassium balance is not disturbed by additional factors (e.g. vomiting, diarrhoea, change in renal function, etc.) checks should be carried out every 4-6 months. If nec ...
Protonil Tablet - Renata Limited
... Pregnant women: No data are available on administration of pantoprazole to pregnant women. However this drug should be used during pregnancy, only if clearly needed. The elderly: No problems with Pantoprzole have been encountered in clinical use in this patient group. Concurrent disease: No dosage a ...
... Pregnant women: No data are available on administration of pantoprazole to pregnant women. However this drug should be used during pregnancy, only if clearly needed. The elderly: No problems with Pantoprzole have been encountered in clinical use in this patient group. Concurrent disease: No dosage a ...
Amitriptylin Abcur film-coated tablet ENG SmPC
... Initial dosage: 25 mg 3 times daily. The dosage is increased in increments of 25 mg, which are primarily added as an evening dose, until the effect has been achieved, usually after 2-3 weeks. The maximum recommended daily dose is 225 mg, occasionally 300 mg for institutionalized patients. If trouble ...
... Initial dosage: 25 mg 3 times daily. The dosage is increased in increments of 25 mg, which are primarily added as an evening dose, until the effect has been achieved, usually after 2-3 weeks. The maximum recommended daily dose is 225 mg, occasionally 300 mg for institutionalized patients. If trouble ...
Antimalarial Drug Toxicity: A Review
... Quinine is associated with a triad of dose-related toxicities when it is given at full therapeutic or excessive doses, e.g. cinchonism, hypoglycemia, and hypotension. Quinine has an -adrenergic blocking effect, and hypotension may occur as a result of vasodilation, myocardial depression, or dysrhy ...
... Quinine is associated with a triad of dose-related toxicities when it is given at full therapeutic or excessive doses, e.g. cinchonism, hypoglycemia, and hypotension. Quinine has an -adrenergic blocking effect, and hypotension may occur as a result of vasodilation, myocardial depression, or dysrhy ...
Prescribing Information
... avoided, monitor for adverse reactions related to the concomitantly administered BCRP substrates, including rosuvastatin. [See Clinical Pharmacology (12.3).] ...
... avoided, monitor for adverse reactions related to the concomitantly administered BCRP substrates, including rosuvastatin. [See Clinical Pharmacology (12.3).] ...
Amerge - GlaxoSmithKline
... Increases in Blood Pressure: Elevations in blood pressure have been reported following use of AMERGE®. At the recommended oral doses, the elevations are generally small (population average maximum increases of < 5 mmHg systolic and < 3 mmHg diastolic at the 2.5 mg dose.) The effects may be more pron ...
... Increases in Blood Pressure: Elevations in blood pressure have been reported following use of AMERGE®. At the recommended oral doses, the elevations are generally small (population average maximum increases of < 5 mmHg systolic and < 3 mmHg diastolic at the 2.5 mg dose.) The effects may be more pron ...
ORAL GLAUCOMA AGENT?
... • Counsel and document for concomitant antibiotic therapy although definite interaction controversial ...
... • Counsel and document for concomitant antibiotic therapy although definite interaction controversial ...
Initiating Depot Antipsychotics
... Initiation of depot antipsychotic medication: Some reports utilize formulas and conversion factors to calculate the dose of a particular depot antipsychotic after oral treatment (this information is adequately reviewed in the CD-ROM on depot antipsychotics, which also contains a useful dosing conver ...
... Initiation of depot antipsychotic medication: Some reports utilize formulas and conversion factors to calculate the dose of a particular depot antipsychotic after oral treatment (this information is adequately reviewed in the CD-ROM on depot antipsychotics, which also contains a useful dosing conver ...
Pradaxa® and Xarelto®: Coming Soon to Your
... This is obviously based upon the procedure planned, the clinical scenario and the likelihood of bleeding complications. For most non-surgical and simple surgical procedures, it would be reasonable to proceed with attention to local hemostatic measures without interruption of anticoagulant therapy. T ...
... This is obviously based upon the procedure planned, the clinical scenario and the likelihood of bleeding complications. For most non-surgical and simple surgical procedures, it would be reasonable to proceed with attention to local hemostatic measures without interruption of anticoagulant therapy. T ...
Prescribing Information
... nitisinone. In these studies, nitisinone was administered to mice and rabbits during organogenesis with oral doses of nitisinone up to 20 and 8 times respectively, the recommended human dose. In mice, nitisinone caused incomplete skeletal ossification of fetal bones and decreased pup survival at dos ...
... nitisinone. In these studies, nitisinone was administered to mice and rabbits during organogenesis with oral doses of nitisinone up to 20 and 8 times respectively, the recommended human dose. In mice, nitisinone caused incomplete skeletal ossification of fetal bones and decreased pup survival at dos ...
Ditripentat-Heyl (DTPA) - Heyl Chemisch
... The acute LD50 of Ca-DTPA is 6.2 g/kg (mouse i.p.), whereas the animals died within 48 hours. In rats the LD50 is 3.5 g/kg (i.p.). b) Chronic toxicity Long-term studies with low doses of Ca-DTPA did not lead to side effects in mice. High doses resulted in nephrotic renal disorders, which are reversi ...
... The acute LD50 of Ca-DTPA is 6.2 g/kg (mouse i.p.), whereas the animals died within 48 hours. In rats the LD50 is 3.5 g/kg (i.p.). b) Chronic toxicity Long-term studies with low doses of Ca-DTPA did not lead to side effects in mice. High doses resulted in nephrotic renal disorders, which are reversi ...
Attachment: Product Information Brivaracetam
... different AEDs showed that patients randomised to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behaviour compared to patients randomised to placebo. In these trials, which had a median treatment duration of 12 weeks, the estim ...
... different AEDs showed that patients randomised to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behaviour compared to patients randomised to placebo. In these trials, which had a median treatment duration of 12 weeks, the estim ...
Corticosteroids
... • For most clinical purposes, synthetic glucocorticoids are used because they have a higher affinity for the receptor, are less activated and have little or no salt-retaining properties. • Hydrocortisone used for: orally for replacement therapy, i.v. for shock and asthma, topically for eczema (ointm ...
... • For most clinical purposes, synthetic glucocorticoids are used because they have a higher affinity for the receptor, are less activated and have little or no salt-retaining properties. • Hydrocortisone used for: orally for replacement therapy, i.v. for shock and asthma, topically for eczema (ointm ...
PACKAGE INSERT TEMPLATE FOR PARACETAMOL
... •Considered to be the analgesic of choice in pregnant patients. •Although it crosses placenta, paracetamol is considered to be safe in normal therapeutic doses for short-term use as a minor analgesic/antipyretic in pregnancy. Use in lactation: •Excreted in breast milk. •Maternal ingestion of paracet ...
... •Considered to be the analgesic of choice in pregnant patients. •Although it crosses placenta, paracetamol is considered to be safe in normal therapeutic doses for short-term use as a minor analgesic/antipyretic in pregnancy. Use in lactation: •Excreted in breast milk. •Maternal ingestion of paracet ...
Lamisil cutaneous spray, solution ENG SmPC
... oral doses of about 100 mg/kg a day. At high oral doses, the liver and possibly also the kidneys were identified as potential target organs. In a two-year oral carcinogenicity study in mice, no neoplastic or other abnormal findings attributable to treatment were made up to doses of 130 (males) and 1 ...
... oral doses of about 100 mg/kg a day. At high oral doses, the liver and possibly also the kidneys were identified as potential target organs. In a two-year oral carcinogenicity study in mice, no neoplastic or other abnormal findings attributable to treatment were made up to doses of 130 (males) and 1 ...
antidotesjbcole1
... – Endogenous hydrolysis and recovery (as with carbamates, such as physostigmine) – Reactivation by a strong nucleophile (e.g. 2-PAM) – “Aging,” which involves biochemical changes to the enzyme that result in permenant dysfunction ...
... – Endogenous hydrolysis and recovery (as with carbamates, such as physostigmine) – Reactivation by a strong nucleophile (e.g. 2-PAM) – “Aging,” which involves biochemical changes to the enzyme that result in permenant dysfunction ...
Non Steroidal Anti-inflammatory Drugs (NSAIDs)
... Acetyl salicylic acid (aspirin). Kinetics: • Well absorbed from the stomach, more from upper small intestine. • Distributed all over the body, 50‐80% bound to plasma protein (albumin). • Metabolized to acetic acid and salicylates (active metabolite). • Salicylate is conjugated with glucuronic a ...
... Acetyl salicylic acid (aspirin). Kinetics: • Well absorbed from the stomach, more from upper small intestine. • Distributed all over the body, 50‐80% bound to plasma protein (albumin). • Metabolized to acetic acid and salicylates (active metabolite). • Salicylate is conjugated with glucuronic a ...
MONITOR: Serotonin reuptake inhibitors (SRIs) may potentiate the
... drugs are coadministered. Lovastatin has been shown to alter the hypoprothrombinemic response to warfarin. Theoretically, no interaction should occur with other oral anticoagulants and atorvastatin, although data is lacking. coumadin (warfarin) and acetaminophen (Ingredient of vicodin) (Minor Drug-D ...
... drugs are coadministered. Lovastatin has been shown to alter the hypoprothrombinemic response to warfarin. Theoretically, no interaction should occur with other oral anticoagulants and atorvastatin, although data is lacking. coumadin (warfarin) and acetaminophen (Ingredient of vicodin) (Minor Drug-D ...
Xarelto, Janssen
... “The use of blood thinners has been shown to safely and effectively help keep people from developing preventable blood clots,” said Alan Brownstein, Chief Executive Officer of the National Blood Clot Alliance. “The FDA approval of a new blood thinner, XARELTO®, offers a new option for patients seek ...
... “The use of blood thinners has been shown to safely and effectively help keep people from developing preventable blood clots,” said Alan Brownstein, Chief Executive Officer of the National Blood Clot Alliance. “The FDA approval of a new blood thinner, XARELTO®, offers a new option for patients seek ...
MAXALT® MAXALT-MLT™
... endings in an activated trigeminal system. The therapeutic activity of rizatriptan in migraine can most likely be attributed to agonist effects at 5-HT1B/1D receptors on the extracerebral, intracranial blood vessels that become dilated during a migraine attack and on nerve terminals in the trigemina ...
... endings in an activated trigeminal system. The therapeutic activity of rizatriptan in migraine can most likely be attributed to agonist effects at 5-HT1B/1D receptors on the extracerebral, intracranial blood vessels that become dilated during a migraine attack and on nerve terminals in the trigemina ...
acetaminophen (oral, rectal) (a-seet-a-min-oh-fen
... mended dose of either drug given alone. Do not exceed maximum daily dose of acetaminophen when considering all routes of administration and all combination products containing acetaminophen. Pain: Assess type, location, and intensity prior to and 30– 60 min following administration. Fever: Assess fe ...
... mended dose of either drug given alone. Do not exceed maximum daily dose of acetaminophen when considering all routes of administration and all combination products containing acetaminophen. Pain: Assess type, location, and intensity prior to and 30– 60 min following administration. Fever: Assess fe ...
Latest data on management of bleeding in patients taking DOACs
... Change of Serine to Alanine to eliminate catalytic activity and prevent prothrombin cleavage GLA domain removed to prevent anticoagulant effect ...
... Change of Serine to Alanine to eliminate catalytic activity and prevent prothrombin cleavage GLA domain removed to prevent anticoagulant effect ...
Dydrogesterone
Dydrogesterone (INN, USAN, BAN), is also chemically known as 9β,10α-pregna-4,6-diene-3,20-dione. Dydrogesterone (6-dehydro-retroprogesterone) is a hormonally active, non-androgenic steroid that was developed in the 1950s.Dydrogesterone has selective progestational activity and does not inhibit ovulation. The greater rigidity of dydrogesterone also positively affects its selectivity, while natural progesterone is less selective, existing in different conformations that more easily bind to different receptors. As a consequence of its better bioavailability and the progestational activity of its main metabolites (20-, 21- and 16-hydroxy derivatives), the equivalent dose of dydrogesterone is 10–20 times lower than that of oral micronized progesterone.Dydrogesterone is used as an effective, orally active progestogen for gynaecological conditions related to a wide variety of progesterone deficiencies in pregnant women. The molecular structure and pharmacological effects are somewhat similar to endogenous progesterone, although in smaller amounts it is found to be orally active. Its freedom from hormonal effects like those related to corticoid, androgenic, estrogenic, anabolic, and other effects gives dydrogesterone an advantage over other synthesized progestogens.Dydrogesterone when used therapeutically is closely related to its physiological action on the neuro-endocrine control of ovarian function, as well as on the endometrium. This is an indication in all cases of endogeneous progesterone deficiency - relative or absolute. The molecule was licensed for use in several indications, including threatened or recurrent miscarriage, dysfunctional bleeding, infertility due to luteal insufficiency, dysmenorrhea, endometriosis, secondary amenorrhoea, irregular cycles, pre-menstrual syndrome and also as a hormone replacement therapy.Dydrogesterone has proven effective in the following conditions associated with progesterone deficiency: Infertility due to luteal insufficiency Threatened miscarriage Habitual or recurrent miscarriage. Menstrual disorders Premenstrual syndrome Endometriosis Dydrogesterone has also been registered as hormone replacement therapy (HRT) to counter-check the negative effects of unopposed estrogen on the endometrium in women with an intact uterus. Dydrogesterone is relatively safe and well tolerated, and does not exhibit the androgenic side effects that are common with some other progestins, like medroxyprogesterone acetate.